EHA 2026

Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches

EHA 2026 discussions focused on individualized hemophilia care, moving beyond standard prophylaxis to tailored treatment strategies based on patient-specific factors.

Macrophages: Dual Role in Haematological Malignancies Explored

Macrophages exhibit a dual role in haematological malignancies, acting as both tumour suppressors and promoters, influencing disease progression and therapeutic responses.

Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026

EHA 2026 will review a quarter-century of molecular hematology, focusing on the integration of genomic data into targeted therapeutic strategies.

Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)

Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.

Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights

Belantamab mafodotin's position in relapsed/refractory multiple myeloma treatment continues to evolve, with new data presented at EHA 2026 refining its application.

Infection Prevention Critical in Hematological Malignancies

Infections remain a leading cause of morbidity and mortality in hematological malignancy patients. Prophylactic strategies are essential.

NDMM Treatment Optimisation: Communication Key to Individualisation

Optimising treatment for newly-diagnosed multiple myeloma (NDMM) requires patient-centred communication to individualise therapy and improve outcomes.

AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility

EHA 2026 data indicates that functional fitness assessments, rather than chronological age, should guide intensive chemotherapy eligibility in AML.

CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations

First-line venetoclax combinations versus BTK inhibitors in chronic lymphocytic leukaemia (CLL): EHA 2026 evidence on venetoclax-obinutuzumab, ibrutinib, and acalabrutinib efficacy, safety, and patient selection criteria.

CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026

EHA 2026 discussions highlight evolving CAR T-cell therapy guidelines for lymphoma and multiple myeloma, focusing on patient selection and sequencing.

BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies

The management of chronic lymphocytic leukemia (CLL) with BTK inhibitors is evolving, necessitating careful consideration of treatment sequencing and resistance mechanisms.

Novel Approaches Address Multiple Myeloma Resistance at EHA 2026

Multiple myeloma treatment faces challenges with resistance. New strategies presented at EHA 2026 offer insights into overcoming these hurdles.

Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review

Review of EHA 2026 data on frontline treatment for lower-risk myelodysplastic syndromes (LR-MDS), focusing on erythroid response and transfusion independence.

DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option

Current bispecific antibody options in relapsed/refractory DLBCL — including epcoritamab and glofitamab as T-cell engager therapies — reviewed for efficacy, safety, and sequencing after CAR-T or prior lines of therapy.

Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma

Bispecific antibodies offer a new treatment avenue for relapsed/refractory multiple myeloma, demonstrating high response rates in heavily pretreated patients.

Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights

Allogeneic cell therapy is a treatment option for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

CD20-Targeted Therapies Remain Central to NHL Management

CD20-directed agents continue to underpin non-Hodgkin lymphoma treatment, with ongoing refinements in antibody-drug conjugates and bispecifics.

Infection Prevention Critical in Hematological Malignancies

Patients with hematological malignancies face a high risk of infection, necessitating proactive prevention strategies to improve outcomes.

CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026

Strategies for initiating and sequencing targeted therapy in CLL must align with patient priorities and evidence for long-term benefit.

ITP Management: Bridging Clinician and Patient Perspectives

Chronic immune thrombocytopenia (ITP) management: a clinical review aligning physician treatment strategies with patient quality-of-life priorities, long-term outcomes, and disease burden in chronic ITP.

CAR T: Speed and Reliability Critical for Patient Outcomes

CAR T-cell therapy for glioblastoma multiforme (GBM) requires rapid, reliable delivery to improve patient outcomes, addressing current translational limitations.

Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026

EHA 2026 discussions on cytopenic myelofibrosis focused on risk stratification and treatment selection, emphasizing ruxolitinib and pacritinib.

FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies

EHA 2026 reviewed current strategies for FLT3-mutated acute myeloid leukaemia, focusing on targeted therapies and their impact on patient outcomes.

Evolving Infection Prevention in HSCT and Cellular Therapies

Infection prevention in allogeneic HSCT and cellular therapies faces challenges from evolving pathogens and treatment modalities. New strategies are emerging.

CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden

Subcutaneous CD38 monoclonal antibody administration in quad therapy for multiple myeloma significantly reduces treatment burden and improves patient experience.

Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026

EHA 2026 discussions on multiple myeloma focused on integrating novel therapies into established treatment algorithms, addressing challenges in patient selection and sequence optimization.

Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma

Bispecific antibodies offer new options for relapsed/refractory follicular lymphoma, particularly after two prior lines of therapy.

Rare Conditions: EHA 2026 Highlights Diagnostic Challenges

EHA 2026 session 'The Sherlock Holmes Approach' addressed diagnostic delays in rare haematological conditions, emphasizing systematic clinical reasoning.

Novel Approaches in R/R MM: Expert Perspectives from EHA 2026

Emerging data from EHA 2026 highlight advancements in relapsed/refractory multiple myeloma, focusing on CAR T-cell therapies and bispecific antibodies.

Immune Drivers in Autoimmune Cytopenias Inform Patient Care

Understanding immune drivers in autoimmune cytopenias, discussed at EHA 2026, offers insights into targeted therapies and improved patient management.

DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies

EHA 2026 explored optimal treatment sequencing for diffuse large B-cell lymphoma (DLBCL) with current therapeutic options.

Caplacizumab Improves iTTP Outcomes in Real-World Settings

Real-world data presented at EHA 2026 confirm caplacizumab's efficacy in immune-mediated thrombotic thrombocytopenic purpura (iTTP), reducing refractory disease and mortality.

Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026

New data presented at EHA 2026 highlight emerging therapeutic strategies for chronic lymphocytic leukemia (CLL) patients progressing after covalent BTK inhibitor (cBTKi) therapy, demonstrating improved progression-free survival and response rates.

BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma

BCMA-directed therapies are emerging as a critical treatment option for relapsed/refractory multiple myeloma, addressing a significant unmet need.

Real-World Data Confirms Proximal Complement Inhibition in PNH

Real-world evidence presented at EHA 2026 validates the efficacy and safety of proximal complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH).

CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026

CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL) presents a complex treatment landscape. EHA 2026 data focuses on refining patient selection and management strategies to improve efficacy and safety.

Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera

New insights from EHA 2026 clarify the role of iron status in erythrocytosis and symptom burden in polycythemia vera patients.

CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma

CAR T-cell therapy demonstrates durable responses in relapsed/refractory large B-cell lymphoma, addressing a critical unmet need.

DLBCL Treatment: Emerging Targeted Therapies at EHA 2026

An expert roundtable at EHA 2026 discussed new and emerging targeted therapies for diffuse large B-cell lymphoma (DLBCL).

CML Survivorship: Beyond Survival to Quality of Life

Chronic myeloid leukemia (CML) management has shifted from survival to quality of life, focusing on treatment-free remission and symptom burden.

CLL First-Line Therapy: Case-Based Insights from EHA 2026

EHA 2026 session explores first-line chronic lymphocytic leukemia (CLL) therapy through interactive case studies, addressing evolving treatment paradigms.

NDMM Treatment Advances: Quadruplet Regimens Show Efficacy

Newly diagnosed multiple myeloma (NDMM) treatment is evolving, with quadruplet regimens demonstrating improved depth of response and progression-free survival.

Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies

Bispecific antibodies offer a new therapeutic avenue for relapsed/refractory non-Hodgkin lymphoma and multiple myeloma, demonstrating encouraging response rates.

AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes

EHA 2026 data challenges current intensive therapy strategies for AML with myelodysplasia-related changes and therapy-related AML.

CLL: EHA 2026 to Address Unmet Needs in Treatment Selection

EHA 2026 will focus on critical questions in chronic lymphocytic leukemia (CLL) care, particularly treatment selection and resistance mechanisms.

IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months

Combination therapy with ivosidenib and azacitidine significantly extends overall survival in newly diagnosed IDH1-mutant AML patients.

MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies

Optimising first-line treatment for haematologic malignancies requires balancing continuous and fixed-duration therapies, with Measurable Residual Disease (MRD) status emerging as a critical determinant.

Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes

Interactive case-based journey at EHA 2026 explores optimal integration of bispecific antibodies in follicular lymphoma management.

AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration

The EHA 2026 session addresses the immediate need for hematologists to integrate AI tools ethically and practically into clinical workflows.

Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis

New data from the Summit and Apex trials demonstrate avapritinib's efficacy in systemic mastocytosis, offering a targeted treatment option.

Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives

EHA 2026 highlighted real-world strategies for optimising transplant outcomes in haemoglobinopathies, focusing on conditioning and graft sources.

DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy

EHA 2026 discussions highlight persistent challenges in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) management, focusing on optimal sequencing and novel agent integration.

FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant

FLT3 inhibitors are increasingly critical in AML management, improving transplant eligibility and post-remission outcomes, with new combination data emerging.

BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026

EHA 2026 data indicates BCMA bispecific antibodies can be integrated into community practice for relapsed/refractory multiple myeloma.

AML Treatment Strategies: Optimising Outcomes in a Complex Disease

Acute myeloid leukemia (AML) presents significant treatment challenges. This review explores current strategies to improve patient outcomes.

JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026

New data from EHA 2026 indicate that combination therapies involving JAK inhibitors may improve outcomes for myelofibrosis patients.

Inflammation Drives Sickle Cell Disease Pathophysiology

Sickle cell disease (SCD) is characterised by chronic inflammation, contributing to vaso-occlusive crises and organ damage. Targeting inflammatory pathways may offer therapeutic avenues.

EHA 2026: Anticipating Advances in Haematological Malignancies

EHA 2026 is expected to feature updates on novel therapies for haematological malignancies, focusing on targeted agents and cellular therapies.